Our Mission
Pioneering a New Era of GPCR Drug Discovery.
The Opportunity
Unlocking the full potential of G protein-coupled receptor (GPCR) drug targets creates the opportunity to develop the next generation of impactful new medicines for patients across therapeutic areas
What we do
Powered by our proprietary, industrial-scale Native Complex Platform™, we are discovering new ways to drug GPCRs
Our industrial-scale platform aims to unlock previously difficult-to-drug GPCRs and has led to the discovery, optimization, and development of our pipeline of oral small molecule drug candidates.
GPCRs regulate physiological processes in nearly every organ system of the human body
Pipeline
Septerna is advancing a deep pipeline of oral small molecule GPCR programs in development and discovery
We are advancing a wholly-owned pipeline focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
About Us
World-class team of drug hunters, GPCR experts, drug developers, and company builders
We are a strong, values-driven organization aimed at advancing cutting-edge science and relentlessly focused on developing a portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches for patients with significant unmet needs.
Collaboration powers our community
Press Releases
Latest News
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R ...
Septerna to Present at TD Cowen 45th Annual Health Care Conference
Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present ...
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical ...
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership ...
No results found.